Targeting CD123 in acute myeloid leukemia using a T-cCell-Directed dual-Affinity retargeting platform

Blood

Volumn 127, Issue 1, 2016, Pages 122-131

  Al Hussaini, Muneera ^a   Rettig, Michael P ^a   Ritchey, Julie K ^a   Karpova, Darja ^a   Uy, Geoffrey L ^a   Eissenberg, Linda G ^a   Gao, Feng ^b   Eades, William C ^a   Bonvini, Ezio ^c   Chichili, Gurunadh R ^c   Moore, Paul A ^c   Johnson, Syd ^c   Collins, Lynne ^b   Dipersio, John F ^a  

^a Division of Oncology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Macro Genics Inc ^*  (United States)

Author keywords

A novel CD33CD123 dart agent induces t cell target specific association; Activation; And proliferation; The CD33CD123 dart induces a dose Dependent killing of AML cell lines and primary AML blasts in vitro and in vivo

Indexed keywords

ANTIBODY; CD123 ANTIBODY; CD123 ANTIGEN; CD3 ANTIBODY; POLYPEPTIDE; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD3 ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; T LYMPHOCYTE RECEPTOR GENE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; APOPTOSIS; CELL PROLIFERATION; FLOW CYTOMETRY; GENES, T-CELL RECEPTOR ALPHA; GENES, T-CELL RECEPTOR BETA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955453336     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-575704     Document Type: Article

References (30)

1. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013;31(11):621-632.
2. Johnson S, Burke S, Huang L, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010; 399(3):436-449.
3. Moore PA, Zhang W, Rainey GJ, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood. 2011;117(17):4542-4551.
4. Agis H, Fureder W, Bankl HC, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology. 1996;87(4):535-543.
5. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777-1784.
6. Blalock WL, Weinstein-Oppenheimer C, Chang F, et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 1999;13(8): 1109-1166.
7. Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: A covert liaison unveiled. Oncogene. 2000;19(21):2532-2547.
8. Muñoz L, Nomdedeu JF, Ĺopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86(12):1261-1269.
9. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980-2988.
10. Chichili GR, Huang L, Li H, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):289ra82.
11. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graftversus- leukemia. Blood. 2010;116(1):129-139.
12. Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012;119(17): 3917-3924.
13. Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia. 2003;17(3): 576-584.
14. Wang C, Sanders CM, Yang Q, et al. High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc Natl Acad Sci USA. 2010;107(4): 1518-1523.
15. Rettig MP, Ritchey JK, Prior JL, Haug JS, Piwnica-Worms D, Di Persio JF. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol. 2004;173(6): 3620-3630.
16. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods. 2005;2(8):607-614.
17. Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013; 121(9):1633-1643.
18. Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543-553.
19. Roberts AW, He S, Ritchie D, et al. A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. J Clin Oncol. 2010;28(suppl):e13012.
20. Stein C, Kellner C, Kugler M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol. 2010;148(6):879-889.
21. Kuo SR, Wong L, Liu JS. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel. 2012;25(10): 561-569.
22. Kugler M, Stein C, Kellner C, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol. 2010;150(5): 574-586.
23. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122(18): 3138-3148.
24. Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013; 161(3):389-401.
25. Gill S, Tasian SK, Ruella M, et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343-2354.
26. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014; 28(8):1596-1605.
27. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17(3):385-392.
28. Riethm uller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun. 2012;12:12.
29. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43(6):763-771.
30. Le Dieu R, Taussig DC, Ramsay AG, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009; 114(18):3909-3916.